The guide of the ‘Spanish Society of Medical Oncology’ (SEOM) and the ‘Consensus of Pan-Asian guidelines adapted by ESMO for the Management of metastatic colorectal cancer: JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO, and TOS’, both published in 2018, suggest the use of intense chemotherapy regimens (FOLFOXIRI) associated with bevacizumab in first-line therapy for BRAF mutated mCRC with good clinical status (ECOG 0–1), regardless of sidedness (right colon and left colon) (level of evidence IIB). Here, BRAF is linked to metastatic colorectal cancer.